![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ERVMER61-1 |
Gene summary for ERVMER61-1 |
![]() |
Gene information | Species | Human | Gene symbol | ERVMER61-1 | Gene ID | 339476 |
Gene name | endogenous retrovirus group MER61 member 1 | |
Gene Alias | C1orf99 | |
Cytomap | 1q31.1 | |
Gene Type | other | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
339476 | ERVMER61-1 | S014 | Human | Liver | HCC | 2.24e-23 | 6.68e-01 | 0.2254 |
339476 | ERVMER61-1 | S015 | Human | Liver | HCC | 6.72e-13 | 5.72e-01 | 0.2375 |
339476 | ERVMER61-1 | S016 | Human | Liver | HCC | 5.10e-37 | 1.03e+00 | 0.2243 |
339476 | ERVMER61-1 | S028 | Human | Liver | HCC | 1.51e-02 | 2.19e-01 | 0.2503 |
339476 | ERVMER61-1 | GSM5252126_BPH283PrGF_Via | Human | Prostate | BPH | 1.87e-25 | 5.32e-01 | -0.1771 |
339476 | ERVMER61-1 | GSM5252127_BPH283PrSF_Via | Human | Prostate | BPH | 1.02e-16 | 6.66e-01 | -0.1453 |
339476 | ERVMER61-1 | GSM5252128_BPH327PrGF_Via | Human | Prostate | BPH | 2.24e-27 | 4.70e-01 | -0.1688 |
339476 | ERVMER61-1 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 5.47e-04 | 2.78e-01 | -0.2247 |
339476 | ERVMER61-1 | GSM5252134_BPH511PrG_Fcol_3GEX | Human | Prostate | BPH | 1.13e-06 | 1.84e-01 | -0.1433 |
339476 | ERVMER61-1 | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 7.75e-26 | 4.61e-01 | -0.23 |
339476 | ERVMER61-1 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 1.28e-16 | 3.82e-01 | -0.23 |
339476 | ERVMER61-1 | 048752_1579-all-cells | Human | Prostate | BPH | 3.46e-23 | 3.64e-01 | 0.1008 |
339476 | ERVMER61-1 | 052095_1628-all-cells | Human | Prostate | BPH | 6.58e-16 | 3.53e-01 | 0.1032 |
339476 | ERVMER61-1 | 052099_1652-all-cells | Human | Prostate | BPH | 2.38e-05 | 2.37e-01 | 0.1038 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease | ||
Prostate | ![]() | BPH: Benign Prostatic Hyperplasia |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |